| 胰激肽原酶加厄贝沙坦治疗早期糖尿病肾病的疗效观察 |
| |
| 引用本文： | 李桃荣,宁尚侠,李建英. 胰激肽原酶加厄贝沙坦治疗早期糖尿病肾病的疗效观察[J]. 中国药业, 2013, 0(22): 26-27 |
| |
| 作者姓名： | 李桃荣 宁尚侠 李建英 |
| |
| 作者单位： | 湖北省荆州市中心医院,湖北荆州434020 |
| |
| 摘 要： | 目的观察胰激肽原酶加厄贝沙坦治疗2型糖尿病早期肾病的疗效。方法90例患者维持糖尿病原治疗方案不变，随机均分为两组，对照组口服厄贝沙坦，治疗组在此基础上加用胰激肽原酶。3个月后检测尿白蛋白排泄率变化。结果治疗组和对照组治疗后、各组治疗前后相比较，尿白蛋白排泄率变化有统计学意义（P〈0．01）。结论胰激肽原酶加厄贝沙坦治疗早期糖尿病肾病，可有效减少患者微量白蛋白尿。
|
| 关 键 词： | 2型糖尿病 糖尿病肾病 胰激肽原酶 厄贝沙坦 |
Effect Observation on Kallidinogenase plus Irbesartan in Treatment of Early Diabetic Nephropathy |
| |
| Li Taorong,Ning Shangxia,Li Jianying. Effect Observation on Kallidinogenase plus Irbesartan in Treatment of Early Diabetic Nephropathy[J]. China Pharmaceuticals, 2013, 0(22): 26-27 |
| |
| Authors: | Li Taorong Ning Shangxia Li Jianying |
| |
| Affiliation: | ( Department of Endocrinology, Jingzhau Municipal Central Hospital, Jingzhou, Hubei, China 434020) |
| |
| Abstract: | Objective To observe the efficacy of kallidinogenase plus irbesartan in treating the patients with early type 2 diabetic nephropathy（DN）. Methods 90 cases of early type 2 DN maintained the original diabetic treatment and were randomly divided into 2 groups. The control group took oral irbesartan,while on this basis the treatment group was added with kallidinogenase. The changes of urinary albumin excretion rate （UAER） were examined after 3 months. Results UAER had statistical differences between the treatment group and the control group and between before treatment and after treatment in each group（ P 〈 0.01 ）. Conclusion Kallidinogenase plus irbesartan in treatin~ early DN can effectively lessen microalbnminuria. |
| |
| Keywords: | type 2 diabetes diabetic nephropathy kallidinogenase irbesartan |
| 本文献已被 维普 等数据库收录！ |
